Biggest News Aggregation in the World
๐Ÿ“ฐ Looking Statement News

Page 39 - Looking Statement News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.

Volcon & GLV Award ElectraMeccanica Additional Assembly Contract for Fully Electric STAG at EMV's Mesa, AZ Facility

Volcon Inc. ("Volcon"), the first all-electric, off-road powersports company, and ElectraMeccanica Vehicles Corp. ("ElectraMeccanica"), a designer and manufacturer of electric vehicles revolutionizing the urban driving experience, today jointly...
United States Jordan Davis Susane Docherty Aboutvolcon Inc Volcon Inc Company Annual Report On Form

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

07.04.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merckโ€™s anti-PD-1 therapy, plus LENVIMA, the orally available multiple ...
United States New Zealand Gregory Lubiniecki Corina Dutcus Exchange Commission Merck Co Stock

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy,... | April 7, 2023
United States New Zealand Corina Dutcus Gregory Lubiniecki Oncology At Eisai Inc Merck Co Inc

Moderna, Inc.: MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanomaCAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE
United Kingdom United States Stephen Hoge Luke Mircea Willats Erich Rubin Julie Cunningham

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science